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tant cost-driving factor was drug acquisition (median HC:
€260, CC: €293). Signiﬁcantly fewer prescriptions have
been detected in the HC for ACE-inhibitors, diuretics,
digitalis, and beta-blockers. HRQL was improved signif-
icantly in both years over two years, the improvement
was slightly better in HC; however, no signiﬁcant differ-
ences could be detected. Therefore a conduct of a CUA
is not yet possible. Safety and efﬁcacy in HC have been
assessed signiﬁcantly better by the treating physicians.
CONCLUSIONS: According to German guidelines, ACE-
inhibitors are recommended as ﬁrst-line therapy for CHF.
The data show that in some cases this conventional
therapy may be replaced by hawthorn-extract with the
same or slightly better outcome. The ﬁnal results of the
study are expected for 2003.
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OBJECTIVE: To compare two methods of assessing costs
of pharmacological treatment of CVI: based on a resource
utilization questionnaire and on a global estimation of
expenditure declared by patients. METHODS: The study
of costs associated with CVI in Poland was performed on
a representative sample of 1000 people over 18 from the
general population. In patients suffering from CVI, data
concerning all the costs related to this illness were col-
lected by trained interviewers. Among the many ques-
tions, patients were asked about oral and local medicines
consumed (in units), as well as about their own global
estimation of monthly expenditure on treatment. Finally,
the costs calculated in the two different ways were com-
pared. Different cost groups: compression therapy, 
surgical and cosmetic operations, diagnostic tests, hospi-
talisation and indirect costs were measured in the tradi-
tional way (and not compared). RESULTS: One hundred
thirty-six people received oral treatment for CVI. The
average global estimation of monthly expenditure on oral
treatment was €16.82. Monthly expenditure based on
resources consumed was equal to €6.12. Local medicines
were used by 186 people. The average global estimation
of monthly expenditure for local treatment was €9.32
compared to €3.08 when calculated on resource utiliza-
tion basis. CONCLUSIONS: The patients’ perception on
how much they spend on their treatment differs to a great
extent from the cost of medicines calculated on a resource
utilisation basis. The cost of treatment can be assessed
accurately on a basis of a well designed resource utilisa-
tion questionnaire and unit cost.
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OBJECTIVES: CHF is a disease associated with high
morbidity and mortality. Some 1–2% of the total health-
care budget is consumed in the management of CHF. Hos-
pital costs account for up to 70% of this expenditure and
readmission rates for patients with a primary diagnosis
of CHF can be as high as 50% within 6 months of being
discharged. The use of spironolactone in patients with
severe CHF, as demonstrated in the RALES study, has
been shown to reduce mortality by 30% and the rate of
hospitalisation by 35%. In this study the cost effective-
ness of spironolactone plus standard therapy compared
with the use of conventional treatment alone was deter-
mined. An investigation of prescribing trends of spirono-
lactone in general practice in Ireland was undertaken to
determine the impact of the evidence from the RALES
study. METHODS: The study was performed through the
design of a Markov model. The cost data and mortality
and hospital readmission rates for patients on standard
therapy were obtained from a cohort of patients attend-
ing our hospital over a 12-month period. Outcome data
for the spironolactone arm was obtained from the RALES
study. A community prescription database was used 
to analyse prescribing trends for spironolactone from
January 1998 to November 2001. RESULTS: The incre-
mental cost effectiveness ratio (ICER) for spironolactone
therapy was €466 per life year gained (LYG). Sensitivity
analysis demonstrates an ICER range of €75/LYG to
€1136/LYG under a variety of assumptions. A threefold
rise in the proportion of patients prescribed spironolac-
tone following the publication of the RALES study was
observed. CONCLUSIONS: Following publication of the
RALES study a threefold increase in the number of pre-
scriptions for spironolactone has been observed. This
study suggests that the use of spironolactone for patients
with severe CHF is cost effective in the Irish healthcare
setting.
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OBJECTIVES: Atherosclerosis is a disease with relevant
epidemiologic and economic consquences; in 1999,
